Nykode Therapeutics Denmark A/S: Financial statements 2024
CVR: 42038660
Source: annual report 2024, Danish Business Authority
01/01/2024 – 31/12/2024
Nykode Therapeutics Denmark A/S (CVR 42038660) has filed annual accounts for 2024. In 2024, the company reported a gross profit of DKK 63,552,511 and a net result of DKK 156,959 compared with DKK 2,484,505 the year before. That is an increase of 20.1% compared with the year before. Equity in the 2024 report amounted to DKK 5,514,972. The solvency ratio was 27%. The company had 31 employees in the financial year.
- Gross Profit
- DKK 63,552,511
- Profit/Loss
- DKK 156,959
- Equity
- DKK 5,514,972
- Total Assets
- DKK 20,422,248
- Employees
- 31
Development
| Year | Revenue | Gross Profit | Profit/Loss | Equity | Employees |
|---|---|---|---|---|---|
| 2024 | - | 63.6M | 157K | 5.5M | 31 |
| 2023 | - | 52.9M | 2.5M | 5.4M | 31 |
| 2022 | - | 38.6M | 1.9M | 2.9M | 23 |
| 2021 | - | 10.6M | 578K | 978K | 7 |
Official annual report
Screen every Danish company
Combine filters on financials, industry, geography, property and risk, and instantly see which companies match.
Try company screeningEvents in 2024
Nykode Therapeutics Denmark A/S has published its annual report for 2023. Gross profit came to DKK 52,927,648, and the net result was DKK 2,484,505.
About Nykode Therapeutics Denmark A/S
Nykode Therapeutics Denmark A/S is a Danish company of the type Aktieselskab based in Kongens Lyngby, founded in 2021. The company is registered under the industry Virksomhedsrådgivning og anden ledelsesrådgivning. The company was previously named Vaccibody Denmark A/S. The management consists of Michael Thyrring Engsig. The board consists of Louise Stubbe (chair), Harald Gurvin and Michael Thyrring Engsig. The company is owned by Nykode Therapeutics ASA. The company has 11 employees (2026). In 2025, the company reported a gross profit of DKK 31,839,001 and a net result of DKK 1,347,127 compared with DKK 156,959 the year before. Equity in the 2025 report amounted to DKK 6,862,099.
